Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Pipeline of Duchenne Muscular Dystrophy Market Reviewed in Research Report for H2 2015


      News provided by

      ReportsnReports

      Mar 02, 2016, 03:00 ET

      Share this article

      Share this article


      PUNE, India, March 2, 2016 /PRNewswire/ --

      ReportsandReports.com adds "Duchenne Muscular Dystrophy - Pipeline Review, H2 2015" to its store, with comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.

      Complete report on H2 2015 pipeline review of Duchenne Muscular Dystrophy with 66 market data tables and 16 figures, spread across 284 pages is available at http://www.reportsnreports.com/reports/453484-duchenne-muscular-dystrophy-pipeline-review-h2-2015.html .

      The report also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

      Companies discussed in this Duchenne Muscular Dystrophy Pipeline Review, H2 2015 report include Acceleron Pharma, Inc., Asklepios BioPharmaceutical, Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Capricor Therapeutics, Inc., Catabasis Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Debiopharm International S.A., Dong-A Socio Group, Editas Medicine, Inc., Eli Lilly and Company, EryDel SPA, FibroGen, Inc., Galapagos NV, Genethon, GTx, Inc., Idera Pharmaceuticals, Inc., Italfarmaco S.p.A., La Jolla Pharmaceutical Company, Marathon Pharmaceuticals, LLC, Marina Biotech, Inc., Merck KGaA, MyoTherix Inc., NicOx S.A., Nippon Shinyaku Co., Ltd., nLife Therapeutics, S.L., Nobelpharma Co., Ltd., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., Prothelia, Inc., PTC Therapeutics, Inc., ReveraGen BioPharma, Inc., Sanofi, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Shire Plc, Summit Therapeutics Plc, Taiho Pharmaceutical Co., Ltd. and Zambon Company S.p.A.

      Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=453484 .

      Drug profile discussed in this research report are AAV1-Foliistatin, ACE-083, alisporivir, Antisense Oligonucleotide for Duchenne Muscular Dystrophy, Antisense Oligonucleotide to Activate Dystrophin for Duchene Muscular Dystrophy, Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD, Antisense Oligonucleotides to Inhibit ACVR2B for Duchenne Muscular Dystrophy, Antisense RNAi Oligonucleotides for Duchenne Muscular Dystrophy, Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders, arbekacin, ARM-210, AT-300, ataluren, Biostrophin, BMN-044, BMN-045, BMN-053, BMS-986089, CAP-1002, CAT-1004, CAT-1040, CAT-1041, DA-4210, deflazacort, dexamethasone sodium phosphate, domagrozumab, drisapersen, Drug for Duchenne Muscular Dystrophy, Drugs for Duchenne Muscular Dystrophy, DT-200, eteplirsen, FG-3019, Gene Therapy for Duchenne Muscular Dystrophy, Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies, Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy, givinostat, Gtx-027, halofuginone hydrobromide, IB-DMD, idebenone, IMO-8400, LJPC-30Sa, LJPC-30Sb, MG-53, MP-101, Myomir, naproxcinod, NBD Peptide, NS-065, , Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy, Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy, OSX-200, PB-1046, poloxamer, PRO-052, PRO-055, PRT-01, PRT-20, Recombinant Protein for Muscular Dystrophy, Recombinant Protein to Activate Utrophin for Muscular Dystrophies, Recombinant Proteins for Duchenne Muscular Dystrophy, rimeporide, RTC-13, SHP-619, Small Molecule for Duchenne Muscular Dystrophy, Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy, Small Molecules for Duchenne Muscular Dystrophy, Small Molecules to Target Utrophin for Duchenne Muscular Dystrophy, SMT-022357, SMTC-1100, SRP-4008, SRP-4044, SRP-4045, SRP-4050, SRP-4052, SRP-4053, SRP-4055, Stem Cell Therapy for Duchenne Muscular Dystrophy, Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy, Stryka-516, Stryka-969, StrykaPro-1, SYN-01, tadalafil, TAS-205, TVN-102, TXA-127, Verolone and ZP-049.

      Scope of this report: The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

      Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

      About Us:   

      ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


      Contact:
      Ritesh Tiwari
      UNIT no 802, Tower no. 7, SEZ
      Magarpatta city, Hadapsar
      Pune - 411013
      Maharashtra, India.
      + 1 888 391 5441
      [email protected]

      Connect With Us on:
      Facebook: https://www.facebook.com/ReportsnReports/
      LinkedIn: https://www.linkedin.com/company/reportsnreports
      Twitter: https: //twitter.com/marketsreports
      G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
      RSS/Feeds:www.reportsnreports.com/feed/l-latestreports.xml

      SOURCE ReportsnReports

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.